{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:59:50Z","timestamp":1793818790301,"version":"4.6.1"},"reference-count":13,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Extranodal natural killer (NK)\/T-cell lymphoma (ENKTCL) is a rare and aggressive lymphoid malignancy highly associated with Epstein-Barr virus (EBV) infection. Patients with stage III or higher disease often have a poor prognosis. This study retrospectively reviewed the treatment courses of 34 patients with relapsed\/refractory (R\/R) ENKTCL who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center between January 2019 and July 2024. The results showed that in this study, the use of programmed cell death protein 1 inhibitors before transplantation, the number of treatment lines, and whether the plasma EBV was negative or not had no significant impact on overall survival and progression-free survival. Patients achieving complete response or partial response before allo-HSCT exhibited a more favorable prognosis. Conversely, a history of chronic active EBV infection before transplantation and EBV reactivation after transplantation were associated with inferior survival, suggesting poor prognostic outcomes. Genetic susceptibility analysis revealed that patients with advanced ENKTCL frequently harbored hemophagocytic lymphohistiocytosis (HLH)\u2013associated gene variants. LYST gene variants were the most commonly identified HLH-related alterations, and patients developing HLH experienced significantly higher nonrelapse mortality. Furthermore, TP53 gene variants were associated with post\u2013allo-HSCT relapse. In conclusion, allo-HSCT may improve survival in selected patients with high-risk, advanced-stage R\/R ENKTCL. These single-center, retrospective findings are hypothesis-generating and require validation in larger, multicenter studies with longer follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020407","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:30:48Z","timestamp":1783726248000},"page":"6890-6899","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic HSCT may improve survival in advanced extranodal NK\/T-cell lymphoma: a single-center retrospective study"],"prefix":"10.1182","volume":"10","author":[{"given":"Zhihui","family":"Li","sequence":"first","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianxuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Wen","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Fei","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Zhai","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyang","family":"Ming","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-2799","authenticated-orcid":false,"given":"Yanzhi","family":"Song","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Beijing GoBroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"13","key":"2026102711115700600_bib1","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1182\/bloodadvances.2020001852","article-title":"First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK\/T-cell lymphoma: a retrospective analysis from the CLCG","volume":"4","author":"Qi","year":"2020","journal-title":"Blood Adv"},{"issue":"15","key":"2026102711115700600_bib2","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2026102711115700600_bib3","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"2026102711115700600_bib4","doi-asserted-by":"crossref","first-page":"20241024","DOI":"10.1515\/med-2024-1024","article-title":"The role of auto-HSCT in extranodal natural killer\/T cell lymphoma","volume":"19","author":"Peng","year":"2024","journal-title":"Open Med (Wars)"},{"issue":"9","key":"2026102711115700600_bib5","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/ijc.34672","article-title":"Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK\/T-cell lymphoma: a multi-institutional, real-world study","volume":"153","author":"Wei","year":"2023","journal-title":"Int J Cancer"},{"issue":"7","key":"2026102711115700600_bib6","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41375-023-01924-x","article-title":"Allogeneic hematopoietic stem cell transplantation for NK\/T-cell lymphoma: an international collaborative analysis","volume":"37","author":"Berning","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026102711115700600_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13256-021-02798-2","article-title":"Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer\/T-cell lymphoma: a case report and review of the literature","volume":"15","author":"McGehee","year":"2021","journal-title":"J Med Case Rep"},{"issue":"17","key":"2026102711115700600_bib8","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing L-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026102711115700600_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2026102711115700600_bib10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41409-020-01160-2","article-title":"Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK\/T-cell lymphoma","volume":"56","author":"Song","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2026102711115700600_bib11","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer\/T cell lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026102711115700600_bib12","doi-asserted-by":"crossref","first-page":"832428","DOI":"10.3389\/fonc.2022.832428","article-title":"Progress of hematopoietic stem cell transplantation and radiotherapy in the treatment of extranodal NK\/T cell lymphoma","volume":"12","author":"Terro","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"2026102711115700600_bib13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6890\/2595067\/blooda_adv-2026-020407-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6890\/2595067\/blooda_adv-2026-020407-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:12:05Z","timestamp":1793113925000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/6890\/569670\/Allogeneic-HSCT-may-improve-survival-in-advanced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":13,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020407","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,14]]}}}